In situ vaccination for the treatment of cancer. (Q38727470)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

In situ vaccination for the treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Holbrook E Kohrt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Joshua D Brody

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

1 reference

9 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

315-330

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

Lymphoma: immune evasion strategies

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Dendritic cells in vaccination therapies of human malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Functional responses and costimulator dependence of memory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Oncolytic viruses as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

HSF1 overexpression enhances oncolytic effect of replicative adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Oncolytic Adenoviruses in Cancer Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Potentiating cancer immunotherapy using an oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Steady-state and inflammatory dendritic-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

TLR ligands in the local treatment of established intracerebral murine gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Primary cutaneous follicle center lymphoma associated with alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

LPS/TLR4 signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: induction of potent anti-residual tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

High response rate after intratumoral treatment with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Toll-dependent selection of microbial antigens for presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.120

21 January 2018

Identifiers

DOI

10.2217/IMT.15.120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26860335%20AND%20SRC:MED&resulttype=core&format=json